BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 31749302)

  • 1. Novel targets to cure primary myelofibrosis from studies on Gata1
    Zingariello M; Martelli F; Verachi P; Bardelli C; Gobbo F; Mazzarini M; Migliaccio AR
    IUBMB Life; 2020 Jan; 72(1):131-141. PubMed ID: 31749302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis.
    Spangrude GJ; Lewandowski D; Martelli F; Marra M; Zingariello M; Sancillo L; Rana RA; Migliaccio AR
    Stem Cells; 2016 Jan; 34(1):67-82. PubMed ID: 26439305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The thrombopoietin/MPL axis is activated in the Gata1
    Zingariello M; Sancillo L; Martelli F; Ciaffoni F; Marra M; Varricchio L; Rana RA; Zhao C; Crispino JD; Migliaccio AR
    Blood Cancer J; 2017 Jun; 7(6):e572. PubMed ID: 28622305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin.
    Verrucci M; Pancrazzi A; Aracil M; Martelli F; Guglielmelli P; Zingariello M; Ghinassi B; D'Amore E; Jimeno J; Vannucchi AM; Migliaccio AR
    J Cell Physiol; 2010 Nov; 225(2):490-9. PubMed ID: 20458749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis.
    Gilles L; Arslan AD; Marinaccio C; Wen QJ; Arya P; McNulty M; Yang Q; Zhao JC; Konstantinoff K; Lasho T; Pardanani A; Stein B; Plo I; Sundaravel S; Wickrema A; Migliaccio A; Gurbuxani S; Vainchenker W; Platanias LC; Tefferi A; Crispino JD
    J Clin Invest; 2017 Apr; 127(4):1316-1320. PubMed ID: 28240607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease.
    Migliaccio AR; Martelli F; Verrucci M; Migliaccio G; Vannucchi AM; Ni H; Xu M; Jiang Y; Nakamoto B; Papayannopoulou T; Hoffman R
    Exp Hematol; 2008 Feb; 36(2):158-71. PubMed ID: 18206727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosis.
    Zetterberg E; Verrucci M; Martelli F; Zingariello M; Sancillo L; D'Amore E; Rana RA; Migliaccio AR
    Platelets; 2014; 25(7):539-47. PubMed ID: 24176039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis.
    Vannucchi AM; Bianchi L; Paoletti F; Pancrazzi A; Torre E; Nishikawa M; Zingariello M; Di Baldassarre A; Rana RA; Lorenzini R; Alfani E; Migliaccio G; Migliaccio AR
    Blood; 2005 May; 105(9):3493-501. PubMed ID: 15665119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical studies on the use of a P-selectin-blocking monoclonal antibody to halt progression of myelofibrosis in the Gata1
    Verachi P; Gobbo F; Martelli F; Falchi M; di Virgilio A; Sarli G; Wilke C; Bruederle A; Prahallad A; Arciprete F; Zingariello M; Migliaccio AR
    Exp Hematol; 2023 Jan; 117():43-61. PubMed ID: 36191885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Captopril mitigates splenomegaly and myelofibrosis in the Gata1
    Corey SJ; Jha J; McCart EA; Rittase WB; George J; Mattapallil JJ; Mehta H; Ognoon M; Bylicky MA; Summers TA; Day RM
    J Cell Mol Med; 2018 Sep; 22(9):4274-4282. PubMed ID: 29971909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel interaction between megakaryocytes and activated fibrocytes increases TGF-β bioavailability in the Gata1(low) mouse model of myelofibrosis.
    Zingariello M; Ruggeri A; Martelli F; Marra M; Sancillo L; Ceglia I; Rana RA; Migliaccio AR
    Am J Blood Res; 2015; 5(2):34-61. PubMed ID: 27069753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resident Self-Tissue of Proinflammatory Cytokines Rather Than Their Systemic Levels Correlates with Development of Myelofibrosis in
    Zingariello M; Verachi P; Gobbo F; Martelli F; Falchi M; Mazzarini M; Valeri M; Sarli G; Marinaccio C; Melo-Cardenas J; Crispino JD; Migliaccio AR
    Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis.
    Zingariello M; Martelli F; Ciaffoni F; Masiello F; Ghinassi B; D'Amore E; Massa M; Barosi G; Sancillo L; Li X; Goldberg JD; Rana RA; Migliaccio AR
    Blood; 2013 Apr; 121(17):3345-63. PubMed ID: 23462118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy.
    Ling T; Crispino JD; Zingariello M; Martelli F; Migliaccio AR
    Expert Rev Hematol; 2018 Mar; 11(3):169-184. PubMed ID: 29400094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of CXCR1/2 reduces the emperipolesis between neutrophils and megakaryocytes in the Gata1
    Arciprete F; Verachi P; Martelli F; Valeri M; Balliu M; Guglielmelli P; Vannucchi AM; Migliaccio AR; Zingariello M
    Exp Hematol; 2023 May; 121():30-37. PubMed ID: 36863479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. X-linked thrombocytopenia with thalassemia displays bone marrow reticulin fibrosis and enhanced angiogenesis: comparisons with primary myelofibrosis.
    Åström M; Hahn-Strömberg V; Zetterberg E; Vedin I; Merup M; Palmblad J
    Am J Hematol; 2015 Mar; 90(3):E44-8. PubMed ID: 25421114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows.
    Zetterberg E; Vannucchi AM; Migliaccio AR; Vainchenker W; Tulliez M; Dickie R; Hasselbalch H; Rogers R; Palmblad J
    Haematologica; 2007 May; 92(5):597-604. PubMed ID: 17488682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms.
    Yang N; Park S; Cho MS; Lee M; Hong KS; Mun YC; Seong CM; Huh HJ; Huh J
    Ann Lab Med; 2018 Jul; 38(4):296-305. PubMed ID: 29611379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.
    Wen QJ; Yang Q; Goldenson B; Malinge S; Lasho T; Schneider RK; Breyfogle LJ; Schultz R; Gilles L; Koppikar P; Abdel-Wahab O; Pardanani A; Stein B; Gurbuxani S; Mullally A; Levine RL; Tefferi A; Crispino JD
    Nat Med; 2015 Dec; 21(12):1473-80. PubMed ID: 26569382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.
    Manshouri T; Verstovsek S; Harris DM; Veletic I; Zhang X; Post SM; Bueso-Ramos CE; Estrov Z
    PLoS One; 2019; 14(9):e0222912. PubMed ID: 31569199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.